Jennifer Clark

Dr. Jennifer Clark

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Science Advances
Verified
Journal Article
Open access
MWMelanie R. Walker
Melanie R. Walker
HGHira Lal Goel
Hira Lal Goel
Dimpi MukhopadhyayDimpi Mukhopadhyay
Dimpi Mukhopadhyay
PCPeter Chhoy
Peter Chhoy
EKEmmet R. Karner
Emmet R. Karner
AMArthur M. Mercurio
Arthur M. Mercurio
A specific cell surface glycan enables the identification of breast cancer stem cells and contributes to their function.

1 May 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JMJose Mercado-Matos
Jose Mercado-Matos
JCJennifer Clark
Jennifer Clark
APAndrew J. Piper
Andrew J. Piper
JJJenny Janusis
Jenny Janusis
LSLeslie M. Shaw
Leslie M. Shaw
The insulin receptor substrate (IRS) proteins serve as essential signaling intermediates for the activation of PI3K by both the insulin-like growth factor 1 receptor (IGF-1R) and its close family member, the insulin receptor (IR). Although IRS-1 and IRS-2 share significant homology, they regulate distinct cellular responses downstream of these receptors and play divergent roles in breast cancer. To investigate the mechanism by which signaling through IRS-1 and IRS-2 results in differential outcomes, we assessed the involvement of the microtubule cytoskeleton in IRS-dependent signaling. Treatment with drugs that either stabilize or disrupt microtubules reveal that an intact microtubule cytoskeleton contributes to IRS-2- but not IRS-1-mediated activation of AKT by IGF-1. Proximal IGF-1R signaling events, including IRS tyrosine phosphorylation and recruitment of PI3K, are not inhibited by microtubule disruption, indicating that IRS-2 requires the microtubule cytoskeleton at the level of downstream effector activation. IRS-2 colocalization with tubulin is enhanced upon Taxol-mediated microtubule stabilization, which, together with the signaling data, suggests that the microtubule cytoskeleton may facilitate access of IRS-2 to downstream effectors such as AKT. Of clinical relevance is that our data reveal that expression of IRS-2 sensitizes breast carcinoma cells to apoptosis in response to treatment with microtubule-disrupting drugs, identifying IRS-2 as a potential biomarker for the response of breast cancer patients to Vinca alkaloid drug treatment.

8 August 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
APAndrew J. Piper
Andrew J. Piper
JCJennifer Clark
Jennifer Clark
JMJose Mercado-Matos
Jose Mercado-Matos
AMAsia N. Matthew-Onabanjo
Asia N. Matthew-Onabanjo
CHChung-Cheng Hsieh
Chung-Cheng Hsieh
LSLeslie M. Shaw
Leslie M. Shaw
The insulin-like growth factor-1 (IGF-1) signaling pathway has been implicated in non-small cell lung cancer (NSCLC) outcomes and resistance to targeted therapies. However, little is known regarding the molecular mechanisms by which this pathway contributes to the biology of NSCLC. The insulin receptor substrate (IRS) proteins are cytoplasmic adaptor proteins that signal downstream of the IGF-1R and determine the functional outcomes of this signaling pathway. In this study, we assessed the expression patterns of IRS-1 and IRS-2 in NSCLC to identify associations between IRS-1 and IRS-2 expression levels and survival outcomes in the two major histological subtypes of NSCLC, adenocarcinoma (ADC) and squamous cell carcinoma (SCC). High IRS-2 expression was significantly associated with decreased overall survival in adenocarcinoma (ADC) patients, whereas low IRS-1 cytoplasmic expression showed a trend toward association with decreased overall survival in squamous cell carcinoma (SCC) patients. Tumors with low IRS-1 and high IRS-2 expression were found to be associated with poor outcomes in ADC and SCC, indicating a potential role for IRS-2 in the aggressive behavior of NSCLC. Our results suggest distinct contributions of IRS-1 and IRS-2 to the biology of ADC and SCC that impact disease progression.

1 September 2016 in Human Pathology
Verified
Journal Article
Closed access
JCJennifer Clark
Jennifer Clark
DLDan Lu
Dan Lu
TKTamara Kalir
Tamara Kalir
YLYuxin Liu
Yuxin Liu

1 October 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AKAyush Kumar
Ayush Kumar
HGHira Lal Goel
Hira Lal Goel
CWChristi A Wisniewski
Christi A Wisniewski
TWTao Wang
Tao Wang
YGYansong Geng
Yansong Geng
AMArthur M. Mercurio
Arthur M. Mercurio
The high rate of recurrence after radiation therapy in triple-negative breast cancer (TNBC) indicates that novel approaches and targets are needed to enhance radiosensitivity. Here, we report that neuropilin-2 ( NRP2 ), a receptor for vascular endothelial growth factor ( VEGF ) that is enriched on subpopulations of TNBC cells with stem cell properties, is an effective therapeutic target for sensitizing TNBC to radiotherapy. Specifically, VEGF/NRP2 signaling induces nitric oxide synthase 2 ( NOS2 ) transcription by a mechanism dependent on Gli1. NRP2-expressing tumor cells serve as a hub to produce nitric oxide (NO), an autocrine and paracrine signaling metabolite, which promotes cysteine-nitrosylation of Kelch-like ECH-associated protein 1 ( KEAP1 ) and, consequently, nuclear factor erythroid 2-related factor 2–mediated ( NFE2L2 -mediated) transcription of antioxidant response genes. Inhibiting VEGF binding to NRP2, using a humanized mAb, results in NFE2L2 degradation via KEAP1, rendering cell lines and organoids vulnerable to irradiation. Importantly, treatment of patient-derived xenografts with the NRP2 mAb and radiation resulted in significant tumor necrosis and regression compared with radiation alone. Together, these findings reveal a targetable mechanism of radioresistance, and they support the use of NRP2 mAb as an effective radiosensitizer in TNBC.

22 January 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JCJennifer Clark
Jennifer Clark
KDKaren Dresser
Karen Dresser
CHChung-Cheng Hsieh
Chung-Cheng Hsieh
MSMichael Sabel
Michael Sabel
CKCelina G. Kleer
Celina G. Kleer
LSLeslie M. Shaw
Leslie M. Shaw